Latest Decision Resources Stories
One of the Top Unmet Needs in RA is for Therapies with Greater Ability to Induce Remission Compared with Current Treatments, According to a New Report from Decision Resources BURLINGTON, Mass., June 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of rheumatoid arthritis, the majority of surveyed U.S. and European rheumatologists cite a therapy's induction of...
EU5 Payers Agree that Amid Tightening Healthcare Budgets, the Growing Cost of Brands and Increasing Availability of Generics Makes HIV an Attractive Target for Cost Containment, According to a New Report from Decision Resources BURLINGTON, Mass., June 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the past 12 months, 25 percent of surveyed physicians from the EU5 (France,...
Market Access Tracker Analyzes the Challenges and Opportunities of Gaining and Maintaining Favorable Market Access Terms in 24 Countries BURLINGTON, Mass., June 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announces that its Market Access Tracker service now includes coverage of the Middle East and Africa. Market Access Tracker analyzes the challenges and opportunities to gaining and...
Changes in Reimbursement Policy and an Increasing Incident Population Will Drive Growth Despite Price Cuts in Market, According to a New Report from Decision Resources BURLINGTON, Mass., June 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual rate of 7 percent, reaching $73...
EU5 Payers Indicate that Tightening Budgets Mean Emerging Brands Must Demonstrate Compelling Cost-Effectiveness Over Current Therapies in Order to Justify Reimbursement at a Premium Price, According to a New Report from Decision Resources BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany,...
Overall Survival and Delayed Disease Progression is the Greatest Unmet Need in Platinum-Resistant Advanced Ovarian Cancer, According to a New Report from Decision Resources BURLINGTON, Mass., June 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most...
Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Significant Median Overall Survival Benefit over Currently Available Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists'...
Expansion of Therapies Offering Benefits Over Current Standard of Care Will Drive Growth Despite Price Controls in Market, According to a New Report from Decision Resources BURLINGTON, Mass., June 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2012 to 2017, the hepatitis C virus (HCV) market in Turkey will more than triple, reaching $275 million in 2017. The Emerging...
Efficacy Advantages of TNF-Alpha Inhibitors Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that...
The Commercialization Outlook for Argentina Identifies 16 Key Factors Important for Pharmaceutical Market Access, According to a New Report from Decision Resources BURLINGTON, Mass., May 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that several barriers impede market access but the regulatory landscape in Argentina is changing and attractive opportunities exist for...
